Indaptus Therapeutics is trading 7.4% down at $2.56 as the stock pulls back following several days of sharp gains earlier this week.
- The move comes in the absence of new company-specific headlines, earnings releases, or analyst updates to justify the price action.
- The decline suggests typical volatility and profit-taking within a thinly traded small-cap biotech name.
- The downward pressure occurs against a mixed broader market backdrop.